The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a greater substantial decrease in body weight and benefit metabolic health